Development of a supercritical fluid chromatography–tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study

Matrix effect in bioanalytical assay development using supercritical fluid chromatography-mass spectrometry

Matrix effect (ME) is commonly caused by coelution of compounds with target analytes, resulting in either suppression or enhancement of analyte ionization. Thus, to achieve the desired accuracy, precision, and sensitivity, ME needs to be evaluated and controlled during bioanalytical method development. As the application of supercritical fluid chromatography-mass spectrometry (SFC-MS) for analysis of biological samples has increased, ME using SFC-MS has also been investigated with a focus on the difference in ME in SFC-MS compared to other chromatographic techniques used for achiral separation in biological samples. Here, we provide a summary of the status of ME evaluation and mitigation in SFC-MS methods. This review presents an overview of the phenomenon of ME and methods for evaluating ME in bioanalysis. Next, the factors that can impact ME in SFC-MS-based bioanalytical methods are discussed in detail with an emphasis on SFC. A literature review of the evaluation of ME in targeted bioanalytical methods using SFC-MS is included at the end. Robust instrumentation, effective sample preparation, and superb separation selectivity are the foundations of reliable analytical methods as well as the ability to mitigate detrimental ME in SFC-MS methods.

The simultaneous determination of naringenin and its valine carbamate prodrug in rat plasma using supercritical fluid chromatography -tandem mass spectrometric method

To enhance the oral bioavailability of naringenin, a valine carbamate prodrug was firstly synthesized. It is essential to measure naringenin and its carbamate prodrug simultaneously for evaluating their pharmacokinetic behavior in Sprague-Dawley rats. Here, the samples were analyzed by a supercritical fluid chromatography-tandem mass spectrometric (SFC-MS/MS) method after extracting by liquid-liquid extraction with ethyl acetate. The analytes were eluted completely on an ACQUITY UPC^2TM BEH 2-EP column (3.0 × 100 mm, 1.7 μm) within 2.5 min by gradient elution. The mass transition ion pairs were m/z 273.2→153.0, 416.0→153.1, and 271.2→91.0 for naringenin, the prodrug, and genistein (the internal standard), respectively. Naringenin and the prodrug had excellent linear correlations over the range of 2-1000 ng/mL (r > 0.995) and 4-2000 ng/mL (r > 0.998), with lower limits of quantification of 2 ng/mL and 4 ng/mL, respectively. The intra-day and inter-day precision and accuracy for all quality control samples were within ± 15 %. The high-throughput, sensitive, and economical SFC-MS/MS method was successfully applied to the pharmacokinetic study of naringenin and its carbamate prodrug for the first time. The pharmacokinetic study results showed the total C_max of naringenin in prodrug group was 4.14-fold higher than naringenin group. The higher total AUC value observed with prodrug group indicated increased bioavailability of naringenin as compared to naringenin suspension. The present work provides some helpful information for future studies of naringenin and its carbamate prodrug.

Enhancement of dissolution and oral bioavailability of lacidipine via pluronic P123/F127 mixed polymeric micelles: formulation, optimization using central composite design and in vivo bioavailability study

This study aims at preparing and optimizing lacidipine (LCDP) polymeric micelles using thin film hydration technique in order to overcome LCDP solubility-limited oral bioavailability. A two-factor three-level central composite face-centered design (CCFD) was employed to optimize the formulation variables to obtain LCDP polymeric micelles of high entrapment efficiency and small and uniform particle size (PS). Formulation variables were: Pluronic to drug ratio (A) and Pluronic P123 percentage (B). LCDP polymeric micelles were assessed for entrapment efficiency (EE%), PS and polydispersity index (PDI). The formula with the highest desirability (0.959) was chosen as the optimized formula. The values of the formulation variables (A and B) in the optimized polymeric micelles formula were 45% and 80%, respectively. Optimum LCDP polymeric micelles had entrapment efficiency of 99.23%, PS of 21.08 nm and PDI of 0.11. Optimum LCDP polymeric micelles formula was physically characterized using transmission electron microscopy. LCDP polymeric micelles showed saturation solubility approximately 450 times that of raw LCDP in addition to significantly enhanced dissolution rate. Bioavailability study of optimum LCDP polymeric micelles formula in rabbits revealed a 6.85-fold increase in LCDP bioavailability compared to LCDP oral suspension.

Residue and Dietary Risk Assessment of Chiral Cyflumetofen in Apple

Ultra-performance convergence chromatography is an environmentally-friendly analytical method that uses dramatically reduced amounts of organic solvents. In addition, a robust and highly sensitive chiral separation method was developed for the novel chiral acaricide cyflumetofen by using ultra-performance convergence chromatography coupled with tandem mass spectrometry, which shows that stereoisomer recoveries determined for various apple parts ranged from 78.3% to 119.9%, with the relative standard deviations being lower than 14.0%. The half-lives of (−)-cyflumetofen and (+)-cyflumetofen obtained under 5-fold applied dosage equal to 22.13 and 22.23 days, respectively. For 1.5-fold applied dosage, the respective values were determined as 22.42 and 23.64 days, i.e., the degradation of (−)-cyflumetofen was insignificantly favored over that of its enantiomer. Importantly, cyflumetofen was unevenly distributed in apples, with its relative contents in apple peel, peduncle, and pomace equal to 50%, 22%, and 16%, respectively. The proposed method can be used to efficiently separate and quantify chiral pesticide with advantages of a shorter analysis time, greater sensitivity, and better environmental compatibility. Additionally, the consumption of apples with residue of cyflumetofen did not pose a health risk to the population if the cyflumetofen applied under satisfactory agricultural practices after the long-term dietary risk assessment.

The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo

A biodegradable poly(lactic-co-glycolic acid) loading atorvastatin calcium (AC) nanoparticles (AC-PLGA-NPs) were prepared by probe ultrasonication and evaporation method aiming at improving the oral bioavailability of AC. The effects of experimental parameters, including stabilizer species, stabilizer concentration and pH of aqueous phase, on particle size were also evaluated. The resultant nanoparticles were in spherical shape with an average diameter of 174.7 nm and a narrow particle size distribution. And the drug loading and encapsulation efficiency were about 8% and 71%, respectively. The particle size and polydispersion were almost unchanged in 10 days. The release curves of AC-PLGA-NPs in vitro displaying sustained release characteristics indicated that its release mechanisms were matrix erosion and diffusion. The pharmacokinetic study in vivo revealed that the C_max and AUC_0-∞ of AC-PLGA-NPs in rats were nearly 3.7-fold and 4.7-fold higher than that of pure atorvastatin calcium suspension. Our results demonstrated that the delivery of AC-PLGA-NPs could be a promising approach for the oral delivery of AC for enhanced bioavailability.

Interspecies prediction of oral pharmacokinetics of different lacidipine formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution

PBPK modelling combined with biorelevant dissolution to quantitatively predict dog PK of different lacidipine formulations, and to extrapolate to human.